Inpatient treatment costs of status epilepticus in adults in Germany
Authors:
- Adam StrzelczykASAdam Strzelczyk
- Susanne KnakeSKSusanne Knake
- Wolfgang H. OertelWOWolfgang H. Oertel
- Felix RosenowFRFelix Rosenow
- Hajo M. HamerHHHajo M. Hamer
- 1 December 2013
- journal article
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 22 (10) , 882-885
Abstract
No abstract availableKeywords
Funding Information
- Verein zur Erforschung der Epidemiologie der Epilepsien e.V.
- Desitin
- GlaxoSmithKline
- Janssen-Cilag
- UCB Pharma
This publication has 18 references indexed in Scilit:
- DRG-Systeme in EuropaBundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2012
- Evaluation of health-care utilization among adult patients with epilepsy in GermanyEpilepsy & Behavior, 2012
- Status epilepticus in adultsHandbook of Clinical Neurology, 2012
- Cost of disorders of the brain in Europe 2010European Neuropsychopharmacology, 2011
- The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocolBrain, 2011
- Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide populationEpilepsy Research, 2011
- Cost of EpilepsyPharmacoEconomics, 2008
- Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)Epilepsia, 2005
- Incidence of Status Epilepticus in Adults in Germany: A Prospective, Population‐Based StudyEpilepsia, 2001
- Incidence of status epilepticus in French-speaking SwitzerlandNeurology, 2000